Erythropoietin-induced thrombosis as a result of increased inflammation and thrombin activatable fibrinolytic inhibitor

Clinical and Applied Thrombosis/Hemostasis

Volumn 10, Issue 3, 2004, Pages 225-232

  Tobu, Mahmut ^a   Iqbal, Omer ^a   Fareed, Daniel ^a   Chatha, Maninder ^a   Hoppensteadt, Debra ^a   Bansal, Vinod ^a   Fareed, Jawed ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cytokinesis; Erythropoietin; Nitric oxide; Thrombosis

Indexed keywords

ANTIBODY; C REACTIVE PROTEIN; CITRATE SODIUM; ERYTHROPOIETIN ANTIBODY; NITRIC OXIDE; RECOMBINANT ERYTHROPOIETIN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; UNCLASSIFIED DRUG;

ADULT; AGED; ANALYZER; ANEMIA; ANTIBODY DETECTION; ARTICLE; ATROPHY; BLOOD SAMPLING; CANCER PATIENT; CHRONIC INFLAMMATION; CONTROLLED STUDY; DISEASE ASSOCIATION; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME RELEASE; FEMALE; FIBRINOLYSIS; HEMODIALYSIS; HUMAN; INCIDENCE; INFLAMMATION; KIDNEY CORTEX; KIDNEY CORTEX ATROPHY; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; THORAX PAIN; THROMBOSIS; VEIN THROMBOSIS;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA; AUTOANTIBODIES; C-REACTIVE PROTEIN; CARBOXYPEPTIDASE U; CHRONIC DISEASE; COMPLEMENT ACTIVATION; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; ENZYME INDUCTION; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; FEMALE; FIBRINOLYSIS; HUMANS; INFLAMMATION; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE III; RENAL DIALYSIS; THROMBIN; THROMBOPHILIA; THROMBOSIS;

EID: 3242787246     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/107602960401000304     Document Type: Article

References (12)

1. DeLemos JA, Hillis LD. Diagnosis and management of coronary artery disease in patients with end-stage renal disease on hemodialysis. J Am Soc Nephrol 1996;7:2044.
2. Stenvinkel P, Heimburger O, Paultre F, et al. Strong association between malnutrition, inflammation and atherosclerosis in chronic renal failure. Kidney Int 1999;55:1899.
3. Kooistra M, Niemantsverdriet E, Van Es A, et al. Iron absorption in erythropoietin-treated haemodialysis patients: Effects of iron availability, inflammation and aluminum. Nephrol Dial Transplant 1998;13:82.
4. Allen D, Breen C, Yaqoob M, et al. Inhibition of CFU-E colony formation in uremic patients with inflammatory disease: Role of IFN-γ and TNF-α. J Invest Med 1999;47:204.
5. Steurer M, Sudmeier I, Stauder R, Gasti G. Thromboembolic events in patients with myelodysplastic syndrome receiving thalidomide in combination with darbepoietin-alpha. Br J Haematol 2003;121:101.
6. Wun T, Law L, Harvey D, et al. Increased incidence of symptomatic venous thrombosis in patients with cervical carcinoma treated with concurrent chemotherapy, radiation, and erythropoietin. Cancer 2003;98:1514.
7. Wever R, Boer P, Hijmering M, et al. Nitric oxide production is reduced in patients with chronic renal failure. Circulation 1999;19:1168.
8. Fuste B, Serradell M, Escolar G, et al. Erythropoietin triggers a signaling pathway in endothelial cells and increases the thrombogenicity of their extracellular matrices in vitro. Thromb Haemost 2002;88:678.
9. Verma S, Wang CH, Li SH, et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 2002;106:913.
10. Szmitko PE, Wang CH, Weisel RD, et al. New markers of inflammation and endothelial cell activation: Part I. Circulation 2003;108:1917.
11. Verma S, Li SH, Badiwala MV, et al. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation 2002;105:1890.
12. Kaplanski G, Martin V, Fabrigoule M, et al. Thrombin-activated human endothelial cells support monocyte adhesion molecule-1 (ICAM-1; CD54) and vascular cell adhesion molecule-1 (VCAM-1; CD106). Blood 1998;92:1259.